Biotech Should Keep Rolling

The stocks look like good bets as most tech shares fade

Biotech stocks are a monster roller-coaster. News of a potential blockbuster drug or pending merger--or, conversely, bad results in a clinical trial--can make prices soar or plunge 15% or more in a day. For all their volatility, though, biotechs have racked up big gains this year. Can they continue to buck the tech decline?

To continue reading this article you must be a Bloomberg Professional Service Subscriber.